Bristol-Myers Squibb Company
DE ˙ XTRA ˙ US1101221083
47,44 € ↑0,88 (1,88%)
2026-06-03
DEL PRIS
SecurityDE:BRM / Bristol-Myers Squibb Company
InstitutionPatten Group, Inc.
Latest Disclosed Ownership22,330 shares
Latest Disclosed Value $ 1,354,315
Patten Group, Inc. reports 15.77% increase in ownership of BRM / Bristol-Myers Squibb Company

On April 24, 2026 - Patten Group, Inc. filed a 13F-HR form disclosing ownership of 22,330 shares of Bristol-Myers Squibb Company (DE:BRM) valued at $1,170,539 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 19,288 shares of Bristol-Myers Squibb Company. This represents a change in shares of 15.77% during the quarter. The current value of the position is $1,059,224 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F BRISTOL-MYERS SQUIBB COM 110122108 22,330 3,042 15.77 1,354 30.19 0.2354
2026-01-23 2025-12-31 13F BRISTOL-MYERS SQUIBB COM 110122108 19,288 19,288 1,040 0.1924
2023-10-12 2023-09-30 13F BRISTOL-MYERS SQUIBB COM 110122108 0 -3,267 -100.00 0 -100.00
2023-07-26 2023-06-30 13F BRISTOL-MYERS SQUIBB COM 110122108 3,267 0 0.00 209 -7.96 0.0310
2023-04-06 2023-03-31 13F BRISTOL-MYERS SQUIBB COM 110122108 3,267 0 0.00 226 -3.83 0.0680
2023-02-10 2022-12-31 13F BRISTOL-MYERS SQUIBB COM 110122108 3,267 0 0.00 235 3.07 0.0738
2022-10-13 2022-09-30 13F BRISTOLMYERS SQUIBB COM 110122108 3,267 0 0.00 228 -6.94 0.0783
2022-07-18 2022-06-30 13F BRISTOLMYERS SQUIBB COM 110122108 3,267 0 0.00 245 2.51 0.0785
2022-04-28 2022-03-31 13F BRISTOLMYERS SQUIBB COM 110122108 3,267 0 0.00 239 17.16 0.0670
2022-01-20 2021-12-31 13F BRISTOL-MYERS SQUIBB COM 110122108 3,267 -200 -5.77 204 -0.49 0.0540
2021-11-15 2021-09-30 13F BRISTOL-MYERS SQUIBB COM 110122108 3,467 0 0.00 205 -11.64 0.0603
2021-08-03 2021-06-30 13F BRISTOL-MYERS SQUIBB COM 110122108 3,467 -15 -0.43 232 5.45 0.0682
2021-04-23 2021-03-31 13F BRISTOL-MYERS SQUIBB COM 110122108 3,482 0 0.00 220 1.85 0.0705
2021-02-02 2020-12-31 13F BRISTOL-MYERS SQUIBB COM 110122108 3,482 0 0.00 216 2.86 0.0583
2020-10-19 2020-09-30 13F BRISTOL-MYERS SQUIBB COM 110122108 3,482 0 0.00 210 2.44 0.0819
2020-07-20 2020-06-30 13F BRISTOL-MYERS SQUIBB COM 110122108 3,482 3,482 205 0.0882
2020-04-16 2020-03-31 13F BRISTOL MYERS SQUIBB COM 110122108 0 -3,467 -100.00 0 -100.00
2020-01-14 2019-12-31 13F BRISTOL MYERS SQUIBB COM 110122108 3,467 3,467 223 0.0831
2019-02-12 2018-12-31 13F Bristol-Myers Squibb CS 110122108 0 -4,973 -100.00 0 -100.00
2018-11-14 2018-09-30 13F Bristol-Myers Squibb CS 110122108 4,973 6 0.12 309 12.36 0.1178
2018-08-13 2018-06-30 13F Bristol-Myers Squibb CS 110122108 4,967 -443 -8.19 275 -19.59 0.1102
2018-05-11 2018-03-31 13F Bristol-Myers Squibb CS 110122108 5,410 -128 -2.31 342 0.88 0.1403
2018-02-02 2017-12-31 13F Bristol-Myers Squibb CS 110122108 5,538 -95 -1.69 339 -5.57 0.1343
2017-12-12 2017-09-30 13F/A-1 Bristol-Myers Squibb CS 110122108 5,633 100 1.81 359 15.81 0.1452
2017-11-14 2017-09-30 13F Bristol-Myers Squibb CS 110122108 5,529 -4 359 145,230.6497
2017-08-14 2017-06-30 13F Bristol-Myers Squibb CS 110122108 5,533 -1,182 -17.60 310 -13.65 0.1256
2017-05-30 2017-03-31 13F Bristol-Myers Squibb CS 110122108 6,715 2,181 48.10 359 66.20 0.1558
2017-02-10 2016-12-31 13F Bristol Myers Squibb CS 110122108 4,534 -774 -14.58 216 -18.80 0.0969
2016-11-14 2016-09-30 13F Bristol Myers Squibb CS 110122108 5,308 3 0.06 266 -31.79 0.1250
2016-08-15 2016-06-30 13F Bristol Myers Squibb CS 110122108 5,305 100 1.92 390 17.47 0.1826
2016-05-13 2016-03-31 13F Bristol-Myers Squibb CS 110122108 5,205 500 10.63 332 2.79 0.1578
2016-02-17 2015-12-31 13F Bristol-Myers Squibb CS 110122108 4,705 0 0.00 324 16.19 0.1556
2015-11-16 2015-09-30 13F Bristol-Myers Squibb CS 110122108 4,705 0 0.00 279 -11.18 0.1434
2015-08-24 2015-06-30 13F Bristol-Myers Squibb CS 110122108 4,705 -20 -0.42 313 2.96 0.1487
2015-05-06 2015-03-31 13F BRISTOL MYERS SQUIBB COM 110122108 4,725 0 0.00 304 8.96 0.1557
2015-02-18 2014-12-31 13F BRISTOL MYERS SQUIBB COM 110122108 4,725 4,725 279 0.1355
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.